Regeneus Ltd (RGS)

Sydney
0.011
0.000(0.00%)
  • Volume:
    0
  • Bid/Ask:
    0.011/0.012
  • Day's Range:
    0.011 - 0.011

RGS Overview

Prev. Close
0.011
Day's Range
0.011-0.011
Revenue
300K
Open
0.011
52 wk Range
0.01-0.065
EPS
-0.013
Volume
0
Market Cap
3.37M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
808,813
P/E Ratio
-0.85
Beta
-0.286
1-Year Change
-81.36%
Shares Outstanding
306,436,914
Next Earnings Date
-
What is your sentiment on Regeneus Ltd?
or
Vote to see community's results!

Regeneus Ltd Company Profile

Regeneus Ltd Company Profile

Regeneus Ltd is an Australia-based biotechnology company. The Company is focused on developing regenerative medicine products. The Company uses stem cell technologies to develop cell-based therapies. Its therapeutic areas are focused on osteoarthritis and other musculoskeletal disorders, neuropathic pain and dermatology. The Company’s platform technologies consist of Progenza and Sygenus. Progenza is a cellular therapy targeting pain and inflammation, which uses the secretome to improve Mesenchymal Signalling Cells (MSCs). Progenza repairs local damaged tissue, such as cartilage tissue commonly found in joints like the knees and elbows. Sygenus is a cell-free topical serum and gel treatment for pain and inflammation derived from Adipose MSCs. Sygenus consists of selective bioactive molecules from the secretome. Sygenus reduces pain and inflammation while accelerating tissue healing and repair.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsBuyBuyBuySellStrong Sell
SummaryNeutralNeutralNeutralStrong SellStrong Sell